Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Conatus' $21.8mm FOPO to fund emricasan trials

Executive Summary

Conatus Pharmaceuticals Inc. (hepatic diseases) netted $21.8mm in a follow-on public offering of 4mm shares (including the overallotment) at $5.75. It will use the money to continue developing and prep for registration trials of its Phase II pan-caspase protease inhibitor emricasan in post-liver transplant HCV clearance and liver cirrhosis (including with portal hypertension).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies